Home Cart Sign in  
Chemical Structure| 1333222-12-0 Chemical Structure| 1333222-12-0

Structure of 1333222-12-0

Chemical Structure| 1333222-12-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 1333222-12-0 ]

CAS No. :1333222-12-0
Formula : C12H16BF2NO3
M.W : 271.07
SMILES Code : CC1(C)C(C)(C)OB(C2=CN=C(OC(F)F)C=C2)O1
MDL No. :MFCD18909371
InChI Key :IUBRIOQSSWUJOP-UHFFFAOYSA-N
Pubchem ID :71238325

Safety of [ 1333222-12-0 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H332-H335
Precautionary Statements:P261-P280-P305+P351+P338

Computational Chemistry of [ 1333222-12-0 ] Show Less

Physicochemical Properties

Num. heavy atoms 19
Num. arom. heavy atoms 6
Fraction Csp3 0.58
Num. rotatable bonds 3
Num. H-bond acceptors 6.0
Num. H-bond donors 0.0
Molar Refractivity 67.31
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

40.58 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

0.0
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

3.09
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

2.82
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

0.96
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

1.74
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

1.72

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-3.5
Solubility 0.0851 mg/ml ; 0.000314 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-3.61
Solubility 0.0666 mg/ml ; 0.000246 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-3.97
Solubility 0.0289 mg/ml ; 0.000107 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

Yes
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-5.76 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

1.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<0.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

3.0

Application In Synthesis of [ 1333222-12-0 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 1333222-12-0 ]

[ 1333222-12-0 ] Synthesis Path-Upstream   1~4

  • 1
  • [ 61676-62-8 ]
  • [ 1333222-12-0 ]
YieldReaction ConditionsOperation in experiment
86%
Stage #1: With TurboGrignard In tetrahydrofuran at 0 - 20℃; for 2 h;
Stage #2: for 1.16667 h;
Example 47
Preparation of 2-(difluoromethoxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
5-Bromo-2-(difluoromethoxy)pyridine (1.0 g, 4.5 mmol) was dissolved in dry THF (10 mL), cooled to 0° C., and treated in portions with isopropylmagnesium lithium chloride complex (1.3 M; 3.3 mL, 4.3 mmol).
The mixture was allowed to warm to 20° C., stirred for 2 h, treated with 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (910 μl, 4.3 mmol) and stirred for 70 min more.
The mixture was quenched with saturated ammonium chloride (NH4Cl; 5 mL) and partitioned between ethyl acetate and water.
The organic phase was washed with saturated NaCl, dried (Na2SO4), and evaporated to provide the title compound as a brown oil that was used without further purification (1.1 g, 86percent): 1H NMR (400 MHz, CDCl3) 8.54 (dd, J=1.9, 0.6 Hz, 1H), 8.07 (dd, J=8.2, 1.9 Hz, 1H), 7.54 (t, J=73.0 Hz, 2H), 6.87 (dd, J=8.2, 0.8 Hz, 1H), 1.34 (s, 13H); 19F NMR (376 MHz, CDCl3) δ -89.22.
References: [1] Patent: US2014/274703, 2014, A1, . Location in patent: Paragraph 0295; 0296.
  • 2
  • [ 1054483-78-1 ]
  • [ 1895-39-2 ]
  • [ 1333222-12-0 ]
YieldReaction ConditionsOperation in experiment
53% at 80℃; Sealed tube In a sealed tube was added 2-hydroxy-5-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)pyridine (300 mg, 1.357 mmol), sodium chlorodifluoroacetate (320 mg, 2.036 mmol) in acetonitrile (5 mL). This suspension was heated to 80°C and stirred overnight. The reaction mixture was cooled down to rt, diluted with EtOAc, washed with an aqueous solution of NaHC03 and brine. The organic layer dried over MgS04, filtered and evaporated. Purification by flash chromatography on silica gel (CH2CI2/MeOH, 95/5) gave the title compound (197 mg, 53percent yield). MS: 272.8 [M+H]+, Rt (6) = 3.12 min.
53% at 80℃; Sealed tube 2-Difluoromethoxy-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridine
In a sealed tube was added 2-hydroxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (300 mg, 1.357 mmol), sodium chlorodifluoroacetate (320 mg, 2.036 mmol) in acetonitrile (5 mL).
This suspension was heated to 80° C. and stirred overnight.
The reaction mixture was cooled down to rt, diluted with EtOAc, washed with an aqueous solution of NaHCO3 and brine.
The organic layer dried over MgSO4, filtered and evaporated.
Purification by flash chromatography on silica gel (CH2Cl2/MeOH, 95/5) gave the title compound (197 mg, 53percent yield). MS: 272.8 [M+H]+, Rt(6)=3.12 min.
References: [1] Patent: WO2013/57711, 2013, A1, . Location in patent: Page/Page column 49.
[2] Patent: US2015/342951, 2015, A1, . Location in patent: Paragraph 0859-0860.
  • 3
  • [ 1895-39-2 ]
  • [ 269409-70-3 ]
  • [ 1333222-12-0 ]
YieldReaction ConditionsOperation in experiment
53% at 80℃; Sealed tube In a sealed tube was added 2-hydroxy-5-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)pyridine (300 mg, 1.357 mmol), sodium chlorodifluoroacetate (320 mg, 2.036 mmol) in acetonitrile (5 mL). This suspension was heated to 80°C and stirred overnight. The reaction mixture was cooled down to rt, diluted with EtOAc, washed with an aqueous solution of NaHC03 and brine. The organic layer dried over MgS04, filtered and evaporated. Purification by flash chromatography on silica gel (CH2CI2/MeOH, 95/5) gave the title compound (197 mg, 53percent yield). MS: 272.8 [M+H]+, Rt (6) = 3.12 min.
References: [1] Patent: WO2013/88404, 2013, A1, . Location in patent: Page/Page column 96.
  • 4
  • [ 13466-38-1 ]
  • [ 1333222-12-0 ]
References: [1] Patent: US2014/274703, 2014, A1, .
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 1333222-12-0 ]

Fluorinated Building Blocks

Chemical Structure| 1333319-76-8

A116785 [1333319-76-8]

3-Fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-ol

Similarity: 0.76

Chemical Structure| 444120-95-0

A197554 [444120-95-0]

2-Fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine

Similarity: 0.72

Chemical Structure| 719268-92-5

A140692 [719268-92-5]

3-Fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine

Similarity: 0.71

Chemical Structure| 947249-01-6

A186218 [947249-01-6]

5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(trifluoromethyl)pyridin-2-amine

Similarity: 0.66

Chemical Structure| 458532-86-0

A119324 [458532-86-0]

2-Fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine

Similarity: 0.65

Organoborons

Chemical Structure| 871839-91-7

A128909 [871839-91-7]

2-Isopropoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine

Similarity: 0.89

Chemical Structure| 1257553-85-7

A220871 [1257553-85-7]

2-Propoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine

Similarity: 0.88

Chemical Structure| 947191-69-7

A402438 [947191-69-7]

2-(Cyclopropylmethoxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine

Similarity: 0.86

Chemical Structure| 1054483-78-1

A872110 [1054483-78-1]

5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-ol

Similarity: 0.85

Chemical Structure| 910036-98-5

A136960 [910036-98-5]

2-(Tetrahydropyran-4-yloxy)-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)pyridine

Similarity: 0.84

Ethers

Chemical Structure| 871839-91-7

A128909 [871839-91-7]

2-Isopropoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine

Similarity: 0.89

Chemical Structure| 1257553-85-7

A220871 [1257553-85-7]

2-Propoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine

Similarity: 0.88

Chemical Structure| 947191-69-7

A402438 [947191-69-7]

2-(Cyclopropylmethoxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine

Similarity: 0.86

Chemical Structure| 910036-98-5

A136960 [910036-98-5]

2-(Tetrahydropyran-4-yloxy)-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)pyridine

Similarity: 0.84

Chemical Structure| 893440-50-1

A160723 [893440-50-1]

2-Methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-amine

Similarity: 0.83

Difluoromethyls

Chemical Structure| 887757-48-4

A165123 [887757-48-4]

2-(4-(Difluoromethoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

Similarity: 0.63

Chemical Structure| 1300750-50-8

A126961 [1300750-50-8]

(2-(Difluoromethoxy)pyridin-3-yl)boronic acid

Similarity: 0.61

Chemical Structure| 960067-33-8

A173355 [960067-33-8]

2-(2-(Difluoromethoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

Similarity: 0.60

Chemical Structure| 864754-48-3

A127149 [864754-48-3]

2-(4-(2,2-Difluoroethoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

Similarity: 0.56

Chemical Structure| 1234319-14-2

A187436 [1234319-14-2]

2-(4-(Difluoromethyl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

Similarity: 0.56

Related Parent Nucleus of
[ 1333222-12-0 ]

Pyridines

Chemical Structure| 871839-91-7

A128909 [871839-91-7]

2-Isopropoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine

Similarity: 0.89

Chemical Structure| 1257553-85-7

A220871 [1257553-85-7]

2-Propoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine

Similarity: 0.88

Chemical Structure| 947191-69-7

A402438 [947191-69-7]

2-(Cyclopropylmethoxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine

Similarity: 0.86

Chemical Structure| 1054483-78-1

A872110 [1054483-78-1]

5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-ol

Similarity: 0.85

Chemical Structure| 910036-98-5

A136960 [910036-98-5]

2-(Tetrahydropyran-4-yloxy)-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)pyridine

Similarity: 0.84